Literature DB >> 23229404

Neuro-oncology: anaplastic oligodendrogliomas-value of early chemotherapy.

François Ducray, Ahmed Idbaih.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229404     DOI： 10.1038/nrneurol.2012.248

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

Authors:  Chetan Bettegowda; Nishant Agrawal; Yuchen Jiao; Mark Sausen; Laura D Wood; Ralph H Hruban; Fausto J Rodriguez; Daniel P Cahill; Roger McLendon; Gregory Riggins; Victor E Velculescu; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Bert Vogelstein; Darell Bigner; Hai Yan; Nickolas Papadopoulos; Kenneth W Kinzler
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

2.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

4.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

Authors:  Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

9.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

10.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Authors:  Yuchen Jiao; Patrick J Killela; Zachary J Reitman; Ahmed B Rasheed; Christopher M Heaphy; Roeland F de Wilde; Fausto J Rodriguez; Sergio Rosemberg; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Chetan Bettegowda; Nishant Agrawal; Eric Lipp; Christopher Pirozzi; Giselle Lopez; Yiping He; Henry Friedman; Allan H Friedman; Gregory J Riggins; Matthias Holdhoff; Peter Burger; Roger McLendon; Darell D Bigner; Bert Vogelstein; Alan K Meeker; Kenneth W Kinzler; Nickolas Papadopoulos; Luis A Diaz; Hai Yan
Journal:  Oncotarget       Date:  2012-07
  10 in total
  2 in total

1.  Remote brain microhaemorrhages may predict haematoma in glioma patients treated with radiation therapy.

Authors:  Augustin Lecler; Frédérique Charbonneau; Dimitri Psimaras; Marie-Astrid Metten; Antoine Gueguen; Khe Hoang Xuan; Loic Feuvret; Julien Savatovsky
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

Review 2.  NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).

Authors:  Zhaomu Zeng; Yueyue Chen; Xiuchao Geng; Yuhao Zhang; Xichao Wen; Qingyu Yan; Tingting Wang; Chen Ling; Yan Xu; Junchao Duan; Kebin Zheng; Zhiwei Sun
Journal:  Int J Oncol       Date:  2022-05-04       Impact factor: 5.884
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.